Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andreas Festa

Showing results (31-40 of 43) with videos related to

Pageof 5
Sort By:
Journal of Molecular Medicine (Berlin, Germany)|October 6, 2025
Leucine-rich α-2 glycoprotein 1 is associated with increased mortality risk in patients with peripheral artery diseaseAxel Muendlein, Andreas Leiherer, Eva Maria Brandtner, et al.
Atherosclerosis|June 27, 2025
Serum leucine-rich α-2 glycoprotein 1 predicts 10-year mortality and vascular events in coronary angiography patientsAxel Muendlein, Andreas Leiherer, Eva Maria Brandtner, et al.
Scientific Reports|January 22, 2025
Contribution of type 2 diabetes to major adverse cardiovascular events (MACE) in a long-term observational study with different stages of atherosclerosisArthur Mader, Dario Haeberli, Barbara Larcher, et al.
Lancet (London, England)|June 12, 2012
Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trialBaptist Gallwitz, Juan Guzman, Francesco Dotta, et al.
Diabetes, Obesity & Metabolism|November 28, 2024
Three decades of glucose-lowering therapy in patients at high cardiovascular risk - A real-world analysisMagdalena Neyer, Johannes B Vogel, Pascal Elsner, et al.
Diabetes|July 30, 2002
Factor analysis of metabolic syndrome using directly measured insulin sensitivity: The Insulin Resistance Atherosclerosis StudyAnthony J G Hanley, Andrew J Karter, Andreas Festa, et al.
Diabetes|June 29, 2004
Metabolic and inflammation variable clusters and prediction of type 2 diabetes: factor analysis using directly measured insulin sensitivityAnthony J G Hanley, Andreas Festa, Ralph B D'Agostino, et al.
The Journal of Clinical Endocrinology and Metabolism|April 8, 2003
Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetesImre Pavo, György Jermendy, Tamas T Varkonyi, et al.
Wiener Klinische Wochenschrift|April 26, 2023
[Other specific types of diabetes and exocrine pancreatic insufficiency (update 2023)]Susanne Kaser, Sabine E Hofer, Lili Kazemi-Shirazi, et al.
Journal of Lipid Research|September 21, 2017
Individual serum saturated fatty acids and markers of chronic subclinical inflammation: the Insulin Resistance Atherosclerosis StudyIngrid D Santaren, Steven M Watkins, Angela D Liese, et al.
Pageof 5

Showing results (31-40 of 43) with videos related to

Sort By:
Pageof 5
Journal of Molecular Medicine (Berlin, Germany)|October 6, 2025
Leucine-rich α-2 glycoprotein 1 is associated with increased mortality risk in patients with peripheral artery diseaseAxel Muendlein, Andreas Leiherer, Eva Maria Brandtner, et al.
Atherosclerosis|June 27, 2025
Serum leucine-rich α-2 glycoprotein 1 predicts 10-year mortality and vascular events in coronary angiography patientsAxel Muendlein, Andreas Leiherer, Eva Maria Brandtner, et al.
Scientific Reports|January 22, 2025
Contribution of type 2 diabetes to major adverse cardiovascular events (MACE) in a long-term observational study with different stages of atherosclerosisArthur Mader, Dario Haeberli, Barbara Larcher, et al.
Lancet (London, England)|June 12, 2012
Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trialBaptist Gallwitz, Juan Guzman, Francesco Dotta, et al.
Diabetes, Obesity & Metabolism|November 28, 2024
Three decades of glucose-lowering therapy in patients at high cardiovascular risk - A real-world analysisMagdalena Neyer, Johannes B Vogel, Pascal Elsner, et al.
Diabetes|July 30, 2002
Factor analysis of metabolic syndrome using directly measured insulin sensitivity: The Insulin Resistance Atherosclerosis StudyAnthony J G Hanley, Andrew J Karter, Andreas Festa, et al.
Diabetes|June 29, 2004
Metabolic and inflammation variable clusters and prediction of type 2 diabetes: factor analysis using directly measured insulin sensitivityAnthony J G Hanley, Andreas Festa, Ralph B D'Agostino, et al.
The Journal of Clinical Endocrinology and Metabolism|April 8, 2003
Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetesImre Pavo, György Jermendy, Tamas T Varkonyi, et al.
Wiener Klinische Wochenschrift|April 26, 2023
[Other specific types of diabetes and exocrine pancreatic insufficiency (update 2023)]Susanne Kaser, Sabine E Hofer, Lili Kazemi-Shirazi, et al.
Journal of Lipid Research|September 21, 2017
Individual serum saturated fatty acids and markers of chronic subclinical inflammation: the Insulin Resistance Atherosclerosis StudyIngrid D Santaren, Steven M Watkins, Angela D Liese, et al.
Pageof 5